• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对创新药物倡议的反思。

Reflections on the Innovative Medicines Initiative.

机构信息

Innovative Medicines Initiative, B-1060 Brussels, Belgium.

出版信息

Nat Rev Drug Discov. 2011 May;10(5):321-2. doi: 10.1038/nrd3434.

DOI:10.1038/nrd3434
PMID:21532547
Abstract

The pharmaceutical industry is developing new collaborative models for drug development. This article discusses the experience so far of the Innovative Medicines Initiative, which is currently the largest public-private partnership that is dedicated to pharmaceutical innovation, highlighting lessons learned for the success of precompetitive consortia.

摘要

制药行业正在为药物研发开发新的合作模式。本文讨论了目前规模最大的专注于制药创新的公私合作伙伴关系——创新药物倡议(Innovative Medicines Initiative,IMI)迄今为止的经验,强调了成功的竞争前联盟的经验教训。

相似文献

1
Reflections on the Innovative Medicines Initiative.对创新药物倡议的反思。
Nat Rev Drug Discov. 2011 May;10(5):321-2. doi: 10.1038/nrd3434.
2
Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.通过公私合作提高制药公司的研发效率:创新药物倡议的经验
Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):545-8. doi: 10.1586/erp.12.59. Epub 2012 Nov 8.
3
The innovative medicines initiative: a European response to the innovation challenge.创新药物倡议:欧洲对创新挑战的回应。
Clin Pharmacol Ther. 2012 Mar;91(3):418-25. doi: 10.1038/clpt.2011.321. Epub 2012 Feb 8.
4
Intellectual property policies in early-phase research in public-private partnerships.公私合营早期研究中的知识产权政策。
Nat Biotechnol. 2016 May 6;34(5):504-10. doi: 10.1038/nbt.3562.
5
Public-private partnership models in France and in Europe.法国及欧洲的公私合作模式。
Therapie. 2006 Jul-Aug;61(4):325-34, 313-23. doi: 10.2515/therapie:2006059.
6
The Innovative Medicines Initiative moves translational immunology forward.创新药物倡议推动转化免疫学向前发展。
Eur J Immunol. 2013 Feb;43(2):298-302. doi: 10.1002/eji.201370024.
7
Open PHACTS: semantic interoperability for drug discovery.Open PHACTS:药物发现的语义互操作性。
Drug Discov Today. 2012 Nov;17(21-22):1188-98. doi: 10.1016/j.drudis.2012.05.016. Epub 2012 Jun 7.
8
Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.通过合作创新促进药物发现:德国癌症研究中心与拜耳健康护理公司之间的一种新颖的风险和回报共享伙伴关系。
Drug Discov Today. 2012 Nov;17(21-22):1242-8. doi: 10.1016/j.drudis.2012.04.004. Epub 2012 Apr 12.
9
Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.公私合营伙伴关系中的控制权分配与合作效率:来自中国制药行业的理论与证据
Int J Health Care Finance Econ. 2009 Jun;9(2):169-82. doi: 10.1007/s10754-009-9063-5. Epub 2009 Apr 10.
10
Academia-pharma partnerships for novel drug discovery: essential or nice to have?学术界与制药公司合作进行新药研发:是必不可少还是可有可无?
Expert Opin Drug Discov. 2017 Jun;12(6):537-540. doi: 10.1080/17460441.2017.1318124. Epub 2017 Apr 17.

引用本文的文献

1
The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.创新药物倡议——公私合作十年。
Front Med (Lausanne). 2019 Dec 3;6:275. doi: 10.3389/fmed.2019.00275. eCollection 2019.
2
New Insights in Computational Methods for Pharmacovigilance: , a Bayesian Framework for Causal Assessment.计算药物警戒学方法的新视角:基于贝叶斯框架的因果评估。
Int J Environ Res Public Health. 2019 Jun 24;16(12):2221. doi: 10.3390/ijerph16122221.
3
"A good collaboration is based on unique contributions from each side": assessing the dynamics of collaboration in stem cell science.

本文引用的文献

1
Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).诊断和定义严重难治性哮喘:创新药物倡议(IMI)的国际共识声明。
Thorax. 2011 Oct;66(10):910-7. doi: 10.1136/thx.2010.153643. Epub 2010 Nov 23.
2
Schizophrenia: The drug deadlock.精神分裂症:药物僵局。
Nature. 2010 Nov 11;468(7321):158-9. doi: 10.1038/468158a.
“良好的合作基于各方独特的贡献”:评估干细胞科学中的合作动态
Life Sci Soc Policy. 2017 Dec;13(1):7. doi: 10.1186/s40504-017-0053-y. Epub 2017 May 4.
4
Inhibition of the dapE-Encoded N-Succinyl-L,L-diaminopimelic Acid Desuccinylase from Neisseria meningitidis by L-Captopril.L-卡托普利对脑膜炎奈瑟菌中dapE编码的N-琥珀酰-L,L-二氨基庚二酸脱琥珀酰酶的抑制作用。
Biochemistry. 2015 Aug 11;54(31):4834-44. doi: 10.1021/acs.biochem.5b00475. Epub 2015 Aug 3.
5
StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium.StemBANCC:在大型干细胞研究联盟中管理材料和数据的访问权限。
Stem Cell Rev Rep. 2015 Oct;11(5):681-7. doi: 10.1007/s12015-015-9599-3.
6
Metrics survey of industry-sponsored clinical trials in Canada and comparator jurisdictions between 2005 and 2010.2005年至2010年加拿大及对照司法管辖区行业赞助临床试验的指标调查。
Healthc Policy. 2012 Nov;8(2):88-104.
7
Integrating pharmacology and clinical pharmacology in pharmaceutical companies.制药公司中整合药理学与临床药理学
Br J Clin Pharmacol. 2012 Jun;73(6):927-30. doi: 10.1111/j.1365-2125.2012.04239.x.
8
Expanding precompetitive space.拓展竞争前空间。
Nat Rev Drug Discov. 2011 Dec;10(12):883. doi: 10.1038/nrd3602.
9
Unraveling the autoimmune translational research process layer by layer.逐层剖析自身免疫性转化医学研究过程。
Nat Med. 2012 Jan 6;18(1):35-41. doi: 10.1038/nm.2632.